The risk of tumor with the use of recombinant human bone morphogenetic proteins clinical trials in a wide population over a longer timeframe ©
Mukhametov U.F., Lyulin S.V., Borzunov D
Heterotopic ossification as a side effect of the use of recombinant human bone morphogenetic proteinsMukhametov, U.F.,
Lyulin, S.V.,
Borzunov, D.Y.,
Gareev, I.F.,
Beylerli, O.A.,
Sufianov, A.A. . ©
Mukhametov U.F., Lyulin S.V., Borzunov D.Yu., Gareev I.F., Beylerli O.A., Sufianov A.A., 2022